Eagle Asset Management Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Eagle Asset Management Inc. lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.6% in the 3rd quarter, Holdings Channel reports. The fund owned 621,363 shares of the company’s stock after selling 58,671 shares during the quarter. Eagle Asset Management Inc.’s holdings in Neurocrine Biosciences were worth $78,130,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. HealthInvest Partners AB grew its stake in shares of Neurocrine Biosciences by 156.5% in the 3rd quarter. HealthInvest Partners AB now owns 60,607 shares of the company’s stock valued at $6,983,000 after buying an additional 36,977 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Neurocrine Biosciences by 4.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 163,054 shares of the company’s stock valued at $18,787,000 after buying an additional 7,069 shares during the period. Landscape Capital Management L.L.C. purchased a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at approximately $1,001,000. Intech Investment Management LLC grew its stake in shares of Neurocrine Biosciences by 49.3% in the 3rd quarter. Intech Investment Management LLC now owns 102,595 shares of the company’s stock valued at $11,821,000 after buying an additional 33,897 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Neurocrine Biosciences by 4.7% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock valued at $94,478,000 after buying an additional 37,098 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent analyst reports. Royal Bank of Canada decreased their price objective on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Raymond James restated an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Jefferies Financial Group increased their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, Citigroup increased their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $125.00 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $109.77 and a 1 year high of $157.98. The company has a market capitalization of $12.66 billion, a P/E ratio of 33.51 and a beta of 0.35. The company’s fifty day moving average is $118.48 and its two-hundred day moving average is $132.18.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.